Research Symposium Agenda

Agenda as of June 19, 2026. Subject to change. All session times are in Mountain Time (MT).

Toggle filters
Date Time Name Session Type More Info
Tuesday, July 28, 2026
Tuesday, July 28, 20264:00 PM - 6:00 PMResearch Symposium Registration & Information DeskRegistration

Toggle filters
Date Time Name Session Type More Info
Wednesday, July 29, 2026
Wednesday, July 29, 20267:00 AM - 5:30 PMResearch Symposium Registration & Information DeskRegistration
Wednesday, July 29, 20268:30 AM - 8:50 AMWelcome & Opening RemarksPresentation
Wednesday, July 29, 20268:50 AM - 9:20 AMNew Therapeutic Opportunities in Angelman Syndrome: How AI Is Changing Drug DiscoveryPresentation
Wednesday, July 29, 20269:25 AM - 9:55 AMUnlocking Critical Periods of Brain PlasticityPresentation
Wednesday, July 29, 202610:00 AM - 10:15 AMThalamocortical Mechanisms of Delta Oscillations in Ube3a^m-/p+ MiceAbstract
Wednesday, July 29, 202610:15 AM - 10:35 AMOpen Discussion & BreakNetworking Break
Wednesday, July 29, 202610:35 AM - 11:05 AMTowards a Common Framework for UBE3A in Angelman Syndrome and CancerPresentation
Wednesday, July 29, 202611:10 AM - 11:25 AMLoss of UBE3A Ligase Activity Drives Phenotypes in an Angelman Syndrome Mouse ModelAbstract
Wednesday, July 29, 202611:25 AM - 12:30 PMLunch BreakWorking Lunch Buffet
Wednesday, July 29, 202612:30 PM - 1:00 PMFruit Flies for the Study of 15q Related SyndromesPresentation
Wednesday, July 29, 20261:05 PM - 1:20 PMInvestigating the Role of HERC2 and HERC2/UBE3A Synergy Toward the Pathogenesis of Dup15q SyndromeAbstract
Wednesday, July 29, 20261:25 PM - 1:55 PMContributions of UBE3A and Non-Imprinted Genes to Angelman Syndrome and Dup15q Syndrome PathophysiologyPresentation
Wednesday, July 29, 20262:00 PM - 2:30 PMWhat do (novel) AS mouse models inform us about UBE3A reinstatement treatments?Presentation
Wednesday, July 29, 20262:30 PM - 2:50 PMOpen Discussion & BreakNetworking Break
Wednesday, July 29, 20262:50 PM - 3:20 PMNickase Cas9 Unsilences Paternal Ube3a in a Mouse Model of Angelman Syndrome Without Causing AAV Vector IntegrationPresentation
Wednesday, July 29, 20263:25 PM - 3:40 PMEpileptiform Spikes in Angelman Syndrome Improve in Response to the UBE3A-ATS Antisense Oligonucleotide RugonersenAbstract
Wednesday, July 29, 20263:45 PM - 4:15 PMNeuronal UBE3A loss engages a TNF-driven neuron-to-microglia axis that promotes synaptic engulfment in Angelman SyndromePresentation
Wednesday, July 29, 20264:20 PM - 4:50 PMAggression Circuit Mapping Across a Transsynaptic Complex in Idic(15) ModelAbstract
Wednesday, July 29, 20264:55 PM - 5:25 PMGaining Insight Into Dup15q Using Human Induced Pluripotent Stem Cell ModelsPresentation
Wednesday, July 29, 20265:30 PM - 5:45 PMUtilizing CRISPR Pooled Screening to Identify Genetic Regulators of Paternal Ube3a SilencingPresentation
Wednesday, July 29, 20265:45 PM - 6:15 PMOpen Discussion & BreakNetworking Break
Wednesday, July 29, 20266:15 PM - 8:15 PMASF & Dup15q Research Symposium Reception and Poster PresentationReception

Toggle filters
Date Time Name Session Type More Info
Thursday, July 30, 2026
Thursday, July 30, 20267:00 AM - 9:30 PMAll-Day Shuttle Service between Embassy Suites & GaylordTransportation
Thursday, July 30, 20267:30 AM - 8:00 AMClosing Breakfast with ASF & DUP15Q AllianceMeal
Thursday, July 30, 20268:00 AM - 8:10 AMOpening Remarks - Day 2Presentation
Thursday, July 30, 20268:10 AM - 8:40 AMFunctional Neuroimaging Biomarkers for Treatment Monitoring in Angelman SyndromePresentation
Thursday, July 30, 20268:45 AM - 9:00 AMProgram Update on MVX-220Program Update
Thursday, July 30, 20269:05 AM - 9:20 AMResults of the Phase 2a Pediatric Study of Alogabat for the Treatment of Angelman Syndrome (ALDEBARAN Study)Program Update
Thursday, July 30, 20269:25 AM - 9:55 AMDevelopment of an ASO targeting UBE3A for Dup15q syndrome using a proprietary AI-enabled CNS drug discovery platformPresentation
Thursday, July 30, 20269:55 AM - 10:15 AMOpen Discussion & BreakNetworking Break
Thursday, July 30, 202610:15 AM - 10:45 AMOverview of the Requirements for a High-Quality Stem Cell BankPresentation
Thursday, July 30, 202610:50 AM - 11:20 AMPreclinical Testing of an ASO Therapy for Dup15q SyndromePresentation
Thursday, July 30, 202611:25 AM - 11:40 AMA Dosage-Sensitive In Vitro Platform for the Quantification of UBE3A-Driven Network Dysfunction and Therapeutic Rescue in Duplication 15q SyndromeAbstract
Thursday, July 30, 202611:45 AM - 12:15 PMModel Systems for Evaluating Therapeutic ASOsPresentation
Thursday, July 30, 202612:20 PM - 12:35 PMComparison of Clinical-Stage ASOs for the Treatment of Angelman Syndrome in a Novel Humanized Ube3a-ATS Mouse ModelAbstract
Thursday, July 30, 202612:35 PM - 1:35 PMLunch BreakMeal
Thursday, July 30, 20261:35 PM - 2:05 PMEvaluation of Individuals With Unsolved Imprinting Conditions Using Long-Read SequencingPresentation
Thursday, July 30, 20262:10 PM - 2:25 PMFrom Pilots to Practice: Exploring and Advancing Newborn Screening for Angelman SyndromeAbstract
Thursday, July 30, 20262:30 PM - 2:50 PMCharacterizing the Angelman Syndrome Sleep Phenotype: Intact Homeostatic Regulation Amidst Impaired Spectral Dynamics and Abnormal Spindle ActivityAbstract
Thursday, July 30, 20262:55 PM - 3:25 PMCharacterization and Quantitation of Movement Disorders in Angelman SyndromeAbstract
Thursday, July 30, 20263:30 PM - 4:00 PMRace, Income, and Representation in Angelman syndrome: Implications for Phenotype Characterization, Care Access, and Trial DesignPresentation
Thursday, July 30, 20264:00 PM - 5:30 PMResearch Symposium Open Discussion / BreakNetworking Break
Thursday, July 30, 20264:30 PM - 5:30 PMAS Natural History Study 20 Year CelebrationReception
Thursday, July 30, 20265:30 PM - 8:30 PMCamp SOAR – Family Welcome ReceptionReception